Which specific long-term safety outcomes are being monitored for tirzepatide?

The short version: the evidence tracks cardiovascular and kidney outcomes out to about four years, but cancer, thyroid, and pancreas risks beyond that are still open questions.

The strongest long-term data comes from the SURPASS-CVOT trial, which followed about 13,000 high-risk patients for a median of four years [2][4]. Tirzepatide beat dulaglutide on a broad heart-and-kidney endpoint, with about 16% fewer events overall [2]. All-cause death was also lower, about 16% fewer [2]. That is real clinical evidence, not a surrogate.

But the comparison matters. Tirzepatide was tested against another drug, dulaglutide, not against no treatment [3][4]. That design can show which drug is better, but it cannot show whether either drug is safe over decades. The trial also enrolled people with established heart disease, so its results do not automatically apply to a healthy person using the drug mainly for weight loss [2][4].

Cancer risk is the biggest unknown. A 2025 review found largely neutral to protective signals overall, but thyroid cancer results were mixed, with some analyses showing increased risk and others showing none [1]. The review explicitly says long-term evaluation is still needed [1]. Pancreatic cancer findings were also inconsistent [1].

Gastrointestinal harm is the known trade-off. A 2026 pharmacovigilance analysis found tirzepatide users had about 2.8 times the reporting odds for gut side effects versus the whole database, with most events starting within three months [5]. That is a signal, not proof of long-term damage.

My call: the evidence supports a heart and kidney benefit in high-risk diabetics over four years, but it cannot answer cancer or thyroid risk beyond that window, and no retrieved study compares long-term users to a genuinely untreated group. Confidence: moderate for the cardiovascular benefit, not clear for long-term cancer and thyroid safety.